3-D structure of enzyme opens path to new drug design in brain disease

March 28, 2017, University of York
Drugs can be designed based on the 3D structure of this human enzyme. Credit: University of York

Researchers at the University of York and Simon Fraser University, Canada, revealed the 3-D structure of an enzyme that could provide a crucial step forward in treating neurodegenerative diseases.

Previous work from these research teams investigated a class of diseases called tauopathies, which occur when tau proteins spontaneously group together in the brain. It is often associated with Alzheimer's and other neurodegenerative diseases.

Research has shown that the tau protein can be modified by a sugar, natural to the body, called O-GlcNAc. This sugar can stabilise the protein to block it from clumping together and may thereby prevent disease. The human O-GlcNAc-hydrolase, however, is responsible for the removal of this crucial sugar from the protein, making it a prime target in preventing the progression of tau-related dementias.

In order to understand how this clumping of tau could be prevented or reduced by increasing O-GlcNAc, scientists at York investigated the structure of the human enzyme to reveal how it is organised to function in this way.

New breakthroughs

Professor Gideon Davies, from the University's Department of Chemistry, said: "Inhibiting the O-GlcNAc-hydrolase enzyme allows scientists to stabilise tau. We have solved the three-dimensional structure of the enzyme in order to aid structure-based design. The unusual and complex organisation should help us in the search for new drugs to treat .

"Drugs can be designed based on the 3-D structure of this human enzyme, which will ultimately pave the way for new breakthroughs in the treatment of diseases such as Alzheimer's."

Professor David Vocadlo, from Simon Fraser University, said: "In addition to serving as a blueprint for the development of antagonists, this long sought after reveals a surprising architecture that may lead to improved understanding of how this important enzyme is regulated in cells. Such insights could lead to more targeted therapeutics for various diseases."

Key to a lock

Dr Rosa Sancho, Head of Research at Alzheimer's Research UK who part-funded this work, said: "Drug discovery is a bit like designing a key to fit a lock, however, it is important to know the shape of the lock you are working with. This new study describes in detail the shape of O-GlcNAc-hydrolase and paves the way for the design of drugs that can fit this lock. Future studies will need to explore whether drugs that can inhibit this enzyme hold promise for treating Alzheimer's and other dementias, but this is an important step in the right direction.

"With 850,000 people in the UK currently living with dementia and no new treatments licensed in the last decade, there is an urgent need for new and innovative strategies to tackle the condition head on."

The research is published in Nature Chemical Biology.

Explore further: Breakthrough in understanding role of enzyme in disease

More information: Christian Roth et al. Structural and functional insight into human O-GlcNAcase, Nature Chemical Biology (2017). DOI: 10.1038/nchembio.2358

Related Stories

Breakthrough in understanding role of enzyme in disease

October 30, 2012

Researchers at the University of Dundee have uncovered the mechanism of an important human enzyme that plays a role in the development of debilitating diseases including cancer, dementia and diabetes.

Researchers test sugary solution to Alzheimer’s

February 26, 2012

(Medical Xpress) -- Slowing or preventing the development of Alzheimer’s disease, a fatal brain condition expected to hit one in 85 people globally by 2050, may be as simple as ensuring a brain protein’s sugar levels ...

Molecular link found between high glucose, metabolic disease

May 5, 2015

Scientists at Johns Hopkins say they've discovered a cause-and-effect link between chronic high blood sugar and disruption of mitochondria, the powerhouses that create the metabolic energy that runs living cells. The discovery, ...

Scientists reveal structure of key cancer target enzyme

November 18, 2015

A team from the University of York has published research unveiling the 3-D structure of human heparanase, a sugar-degrading enzyme which has received significant attention as a key target in anti-cancer treatments.

Recommended for you

New theory shows how strain makes for better catalysts

April 20, 2018

Brown University researchers have developed a new theory to explain why stretching or compressing metal catalysts can make them perform better. The theory, described in the journal Nature Catalysis, could open new design ...

Machine-learning software predicts behavior of bacteria

April 19, 2018

In a first for machine-learning algorithms, a new piece of software developed at Caltech can predict behavior of bacteria by reading the content of a gene. The breakthrough could have significant implications for our understanding ...

Spider silk key to new bone-fixing composite

April 19, 2018

UConn researchers have created a biodegradable composite made of silk fibers that can be used to repair broken load-bearing bones without the complications sometimes presented by other materials.

GLUT5 fluorescent probe fingerprints cancer cells

April 19, 2018

Determining the presence of cancer, as well as its type and malignancy, is a stressful process for patients that can take up to two weeks to get a diagnosis. With a new bit of technology—a sugar-transporting biosensor—researchers ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.